GoodRx rises after offering Lilly weight-loss drugs at discounted self-pay prices

GoodRx Holdings

09/04/2026 12:49

** Shares of telehealth firm GoodRx GDRX.O rise 7% to $2.29 premarket

** Co says it will offer Eli Lilly’s LLY.N newly approved oral weight-loss drug, orforglipron, for eligible self-pay customers starting at $149 a month at over 70,000 U.S. pharmacies

** Co says this is the lowest available cash price at launch for eligible self‑pay customers

** Co says it will also offer self-pay pricing for Lilly’s injectable obesity drug Zepbound, KwikPen, starting at $299 per month

** Move comes as insurance coverage for GLP-1 weight-loss drugs remains uneven, pushing drugmakers and platforms toward direct-to-consumer pricing – GDRX

** GDRX says the partnership aims to improve affordability and access for adults seeking treatment outside insurance

** As of last close, stock down ~21% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))